Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.

Shao L, Hou W, Scharping NE, Vendetti FP, Srivastava R, Roy CN, Menk AV, Wang Y, Chauvin JM, Karukonda P, Thorne SH, Hornung V, Zarour HM, Bakkenist CJ, Delgoffe GM, Sarkar SN.

Cancer Immunol Res. 2019 Aug;7(8):1258-1266. doi: 10.1158/2326-6066.CIR-18-0711. Epub 2019 Jun 25.

PMID:
31239318
2.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.

3.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM.

J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632. [Epub ahead of print]

PMID:
30359157
4.

CD226 opposes TIGIT to disrupt Tregs in melanoma.

Fourcade J, Sun Z, Chauvin JM, Ka M, Davar D, Pagliano O, Wang H, Saada S, Menna C, Amin R, Sander C, Kirkwood JM, Korman AJ, Zarour HM.

JCI Insight. 2018 Jul 26;3(14). pii: 121157. doi: 10.1172/jci.insight.121157. eCollection 2018 Jul 26.

5.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

6.

The microbiome: a basis for novel immunomodulation in mice and men.

Zarour HM.

Clin Adv Hematol Oncol. 2017 Jul;15(7):535-536. No abstract available.

PMID:
28749917
7.

Reversing T-cell Dysfunction and Exhaustion in Cancer.

Zarour HM.

Clin Cancer Res. 2016 Apr 15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849. Review.

8.

Emerging Opportunities and Challenges in Cancer Immunotherapy.

Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I.

Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049. Review.

9.

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.

Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.

10.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM.

J Clin Invest. 2015 May;125(5):2046-58. doi: 10.1172/JCI80445. Epub 2015 Apr 13.

11.

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, Zarour HM.

Cancer Res. 2015 Apr 15;75(8):1635-44. doi: 10.1158/0008-5472.CAN-14-3016. Epub 2015 Feb 26.

12.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

13.

Strategies to reverse melanoma-induced T-cell dysfunction.

Fourcade J, Zarour HM.

Clin Dermatol. 2013 May-Jun;31(3):251-6. doi: 10.1016/j.clindermatol.2012.08.010.

14.

CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.

Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM.

Cancer Res. 2012 Feb 15;72(4):887-96. doi: 10.1158/0008-5472.CAN-11-2637. Epub 2011 Dec 28.

15.

Cancer immunotherapy: Progress and challenges in the clinical setting.

Zarour HM, Ferrone S.

Eur J Immunol. 2011 Jun;41(6):1510-5. doi: 10.1002/eji.201190035. Review. No abstract available.

16.

Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1.

Kudela P, Sun Z, Fourcade J, Janjic B, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2011 Jan 1;186(1):312-22. doi: 10.4049/jimmunol.1001989. Epub 2010 Dec 3.

17.

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM.

J Exp Med. 2010 Sep 27;207(10):2175-86. doi: 10.1084/jem.20100637. Epub 2010 Sep 6.

18.

Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.

Fourcade J, Sun Z, Kudela P, Janjic B, Kirkwood JM, El-Hafnawy T, Zarour HM.

J Immunol. 2010 Jun 15;184(12):6709-18. doi: 10.4049/jimmunol.0903612. Epub 2010 May 10.

19.

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.

J Immunol. 2009 May 1;182(9):5240-9. doi: 10.4049/jimmunol.0803245.

20.

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.

Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM.

J Immunother. 2008 Oct;31(8):781-91. doi: 10.1097/CJI.0b013e318183af0b.

21.

Next generation of immunotherapy for melanoma.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ.

J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423. Review.

PMID:
18612161
22.

Cross-reactive CD4+ T cells against one immunodominant tumor-derived epitope in melanoma patients.

Kudela P, Janjic B, Fourcade J, Castelli F, Andrade P, Kirkwood JM, El-Hefnawy T, Amicosante M, Maillere B, Zarour HM.

J Immunol. 2007 Dec 1;179(11):7932-40.

23.

Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.

Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, Jackson EK, Gorelik E.

Cancer Res. 2007 Jun 15;67(12):5949-56.

24.

Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins.

Castelli FA, Leleu M, Pouvelle-Moratille S, Farci S, Zarour HM, Andrieu M, Auriault C, Ménez A, Georges B, Maillere B.

Eur J Immunol. 2007 Jun;37(6):1513-23.

25.

Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family.

Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B.

Cancer Immunol Immunother. 2007 Jun;56(6):807-18. Epub 2006 Sep 20.

PMID:
16988823
26.

Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.

Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2006 Aug 15;177(4):2717-27.

27.

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM.

J Immunol. 2005 Feb 1;174(3):1751-9.

28.

The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.

Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM.

Cancer Res. 2003 Oct 1;63(19):6506-15.

29.

Melanoma vaccines: early progress and future promises.

Zarour HM, Kirkwood JM.

Semin Cutan Med Surg. 2003 Mar;22(1):68-75. Review.

PMID:
12773015
30.

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R.

Cancer. 2002 Sep 1;95(5):1101-12.

31.

Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes.

Haque MA, Li P, Jackson SK, Zarour HM, Hawes JW, Phan UT, Maric M, Cresswell P, Blum JS.

J Exp Med. 2002 May 20;195(10):1267-77.

32.

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.

Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM.

Cancer Res. 2002 Jan 1;62(1):213-8.

33.

Melanoma antigens recognised by CD8+ and CD4+ T cells.

Storkus WJ, Zarour HM.

Forum (Genova). 2000 Jul-Sep;10(3):256-70. Review.

PMID:
11007933
34.

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM.

Cancer Res. 2000 Sep 1;60(17):4946-52.

35.

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ.

Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5.

Supplemental Content

Loading ...
Support Center